A Randomized, Double-blind, Placebo-Controlled, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 in Subjects With Pulmonary Arterial Hypertension
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Getagozumab (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Gmax Biopharm
- 29 Dec 2021 Planned number of patients changed from 36 to 48.
- 29 Dec 2021 Planned End Date changed from 10 Jun 2022 to 10 Jun 2023.
- 29 Dec 2021 Planned primary completion date changed from 3 Sep 2021 to 26 Oct 2022.